0001125345-24-000007.txt : 20240207 0001125345-24-000007.hdr.sgml : 20240207 20240207161712 ACCESSION NUMBER: 0001125345-24-000007 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240205 FILED AS OF DATE: 20240207 DATE AS OF CHANGE: 20240207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Peters Jeffrey Stuart CENTRAL INDEX KEY: 0001706903 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36112 FILM NUMBER: 24604537 MAIL ADDRESS: STREET 1: 9704 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MACROGENICS INC CENTRAL INDEX KEY: 0001125345 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9704 MEDICAL CENTER DRIVE CITY: Rockville STATE: MD ZIP: 20850 BUSINESS PHONE: 301-251-5172 MAIL ADDRESS: STREET 1: 9704 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 4 1 wk-form4_1707340620.xml FORM 4 X0508 4 2024-02-05 0 0001125345 MACROGENICS INC MGNX 0001706903 Peters Jeffrey Stuart 9704 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 0 1 0 0 Senior VP and General Counsel 1 Common Stock 2024-02-05 4 M 0 54376 11.50 A 54376 D Common Stock 2024-02-05 4 M 0 21875 10.15 A 76251 D Common Stock 2024-02-05 4 S 0 54376 16.50 D 21875 D Common Stock 2024-02-05 4 S 0 21875 16.50 D 0 D Employee stock option (right to buy) 11.50 2024-02-05 4 M 0 54376 0 D 2030-02-20 Common Stock 54376 10875 D Employee stock option (right to buy) 10.15 2024-02-05 4 M 0 21875 0 D 2032-02-22 Common Stock 21875 48125 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/10/2022. 12.5% of the shares underlying the grant became exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter. /s/ Lynn M. Cilinski, Attorney-in-fact 2024-02-07